Biochemical Systems International
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biochemical Systems International - overview
Established
1991
Location
Arezzo, -, Italy
Primary Industry
Medical Devices & Equipment
About
Biochemical Systems International specializes in innovative technology solutions that enhance operational efficiency through real-time data analytics and project management platforms, serving diverse sectors including logistics, healthcare, and finance. Founded in 1991 and headquartered in Arezzo, Italy, Biochemical Systems International focuses on developing technology solutions to improve business operations. The company was acquired by Star Capital in July 2017, gaining a controlling interest. Emilio Dellepiane serves as the CEO.
Biochemical Systems International's core offerings include a cloud-based platform designed for real-time data analytics and project management. This platform is aimed at various industries, such as logistics, healthcare, and finance, and addresses specific challenges like supply chain optimization and regulatory compliance. The product has gained traction among small to medium-sized enterprises (SMEs) and larger corporations across North America and Europe, focusing on user-friendly interfaces and strong performance metrics. In the most recent fiscal year 2023, Biochemical Systems International reported a revenue of USD 19.
46 mn and an EBITDA of USD 2. 89 mn, primarily generated through a subscription-based model that allows clients access to its software on a recurring basis. Biochemical Systems International plans to launch new products aimed at further enhancing its technology offerings, although specific release dates are not available. The company is targeting expansion into additional markets in North America and Europe by 2025, leveraging recent funding to support these initiatives.
The acquisition by Star Capital in July 2017 is anticipated to bolster their growth strategy by enabling greater resource allocation towards product development and market expansion.
Current Investors
Star Capital
Primary Industry
Medical Devices & Equipment
Sub Industries
Monitoring Equipment, Diagnostic Equipment
Website
www.biosys.it
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Biochemical Systems International - timeline of key events
Biochemical Systems International - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 3,670,174 | 4,220,694 | 4,788,096 | 4,684,523 | 4,933,966 | 7,377,161 | 18,054,182 | 13,244,482 | 17,724,569 | 16,006,620 | 14,303,373 | 13,546,555 | - | - | - |
| % Revenue Growth (YoY) | - | 15.0% | 13.4% | (2.2%) | 5.3% | 49.5% | 144.7% | (26.6%) | 33.8% | (9.7%) | (10.6%) | (5.3%) | - | - | - |
| EBITDA (USD) | 575,502 | 470,627 | 243,315 | 299,890 | 511,801 | 1,042,869 | 3,509,269 | 1,877,279 | 2,841,827 | 1,790,202 | 1,376,592 | 437,183 | - | - | - |
| Operating Income (USD) | 260,981 | 162,952 | (30,723) | 121,785 | 298,127 | 941,985 | 3,373,113 | 843,070 | 1,652,552 | 511,391 | 572,200 | (456,895) | - | - | - |
| Operating Margin | 7.1% | 3.9% | (0.6%) | 2.6% | 6.0% | 12.8% | 18.7% | 6.4% | 9.3% | 3.2% | 4.0% | (3.4%) | - | - | - |
| % EBITDA Margin | 15.7% | 11.2% | 5.1% | 6.4% | 10.4% | 14.1% | 19.4% | 14.2% | 16.0% | 11.2% | 9.6% | 3.2% | - | - | - |
| NET Income (USD) | 44,804 | 35,731 | 59,191 | 55,914 | 141,264 | 639,770 | 2,292,328 | 356,664 | 812,580 | 77,830 | 6,424 | (505,085) | - | - | - |
| % Net Margin | 1.2% | 0.8% | 1.2% | 1.2% | 2.9% | 8.7% | 12.7% | 2.7% | 4.6% | 0.5% | 0.0% | (3.7%) | - | - | - |
Biochemical Systems International - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Biochemical Systems International | - |
Displaying 1 - 1 of 1
Biochemical Systems International - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.